Marshall Wace North America’s Ironwood Pharmaceuticals IRWD Stock Holding History

Marshall Wace North America’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-159,157	Closed	-$2.05M	–	1580
2021 Q2	$2.05M	Buy	159,157 +84,047	+112%	+$962K	0.01%	798
2021 Q1	$840K	Buy	+75,110	New	+$793K	﹤0.01%	1088
2020 Q3	–	Sell	-148,924	Closed	-$1.54M	–	1338
2020 Q2	$1.54M	Buy	148,924 +142,155	+2,100%	+$1.45M	0.01%	646
2020 Q1	$68K	Sell	6,769 -48,369	-88%	-$569K	﹤0.01%	1049
2019 Q4	$735K	Sell	55,138 -11,611	-17%	-$128K	﹤0.01%	762
2019 Q3	$573K	Buy	66,749 +5,772	+9%	+$56.1K	﹤0.01%	792
2019 Q2	$667K	Sell	60,977 -9,535	-14%	-$107K	﹤0.01%	838
2019 Q1	$799K	Buy	+70,512	New	+$787K	0.01%	708
2018 Q3	–	Sell	-262,318	Closed	-$4.2M	–	1132
2018 Q2	$4.2M	Buy	+262,318	New	+$3.88M	0.02%	565

Other funds holding IRWD

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Marshall Wace North America's IRWD Position: Q3 2021 in Review

Marshall Wace North America sold out of Ironwood Pharmaceuticals (IRWD) in Q3 2021, closing a stake of 159,157 shares — an estimated $2.05M sold.

Marshall Wace North America first reported a position in IRWD in Q2 2018 and held it in 9 quarters. The position peaked at $4.2M in Q2 2018. 228 funds tracked by Wall St. Rank hold IRWD as of Q3 2021.

Marshall Wace North America reported no remaining Ironwood Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Marshall Wace North America sold 159,157 Ironwood Pharmaceuticals shares in Q3 2021, an estimated $2.05M.
Marshall Wace North America first reported a position in Ironwood Pharmaceuticals in Q2 2018 and held it in 9 quarters.
Marshall Wace North America's Ironwood Pharmaceuticals position peaked at $4.2M in Q2 2018.
228 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.